慢性乙型肝炎肝纤维化患者血清microRNA-122的表达及临床意义

中华传染病杂志 Pub Date : 2018-09-15 DOI:10.3760/CMA.J.ISSN.1000-6680.2018.09.004

Yan Wang, Xiangyu Chen, Ya Li, Yu Wang

{"title":"慢性乙型肝炎肝纤维化患者血清microRNA-122的表达及临床意义","authors":"Yan Wang, Xiangyu Chen, Ya Li, Yu Wang","doi":"10.3760/CMA.J.ISSN.1000-6680.2018.09.004","DOIUrl":null,"url":null,"abstract":"Objective \nTo evaluate the expression of serum microRNA (miRNA)-122 in patients with chronic hepatitis B (CHB) with different stages of liver fibrosis, and to investigate its relevance with the clinical parameters. \n \n \nMethods \nTotally 138 CHB patients and 30 healthy controls were enrolled. Real-time polymerase chain reaction was used to measure the relative expression of miRNA-122 in serum. Serum levels of ALT, AST, γ-glutamyl-transferase (γ-GT), alkaline phosphatase (ALP), total bilirubin (TBil), albumin, prothrombin time (PT) and HBV DNA were measured, and their correlations with serum miRNA-122 were analyzed. Receiver operating characteristic (ROC)curev analysis was performed for miRNA-122 to compare healthy controls and CHB patients with fibrosis. Non-parametric t-test was used for comparison between groups. \n \n \nResults \nThe relative expressions of serum miRNA-122 in patients with CHB and healthy controls were 4.41±1.32 and 1.47±0.58, respectively, with significantly statistical difference (t=3.16, P 0.05). The area under curve (AUC) value for miRNA-122 in the differentiation between CHB patients and control group was 0.92, and the AUC for predicting significant fibrosis and cirrhosis were 0.78 and 0.81, respectively. \n \n \nConclusion \nSerum miRNA-122 is closely related to the replication of HBV, liver damage and liver fibrosis stage. It may play a suppressive role on the HBV replication and the development of liver fibrosis. \n \n \nKey words: \nLiver cirrhosis; Hepatitis B virus; microRNA-122","PeriodicalId":10127,"journal":{"name":"中华传染病杂志","volume":"36 1","pages":"533-536"},"PeriodicalIF":0.0000,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Expression and clinical significance of serum microRNA-122 in liver fibrosis of patients with chronic hepatitis B\",\"authors\":\"Yan Wang, Xiangyu Chen, Ya Li, Yu Wang\",\"doi\":\"10.3760/CMA.J.ISSN.1000-6680.2018.09.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective \\nTo evaluate the expression of serum microRNA (miRNA)-122 in patients with chronic hepatitis B (CHB) with different stages of liver fibrosis, and to investigate its relevance with the clinical parameters. \\n \\n \\nMethods \\nTotally 138 CHB patients and 30 healthy controls were enrolled. Real-time polymerase chain reaction was used to measure the relative expression of miRNA-122 in serum. Serum levels of ALT, AST, γ-glutamyl-transferase (γ-GT), alkaline phosphatase (ALP), total bilirubin (TBil), albumin, prothrombin time (PT) and HBV DNA were measured, and their correlations with serum miRNA-122 were analyzed. Receiver operating characteristic (ROC)curev analysis was performed for miRNA-122 to compare healthy controls and CHB patients with fibrosis. Non-parametric t-test was used for comparison between groups. \\n \\n \\nResults \\nThe relative expressions of serum miRNA-122 in patients with CHB and healthy controls were 4.41±1.32 and 1.47±0.58, respectively, with significantly statistical difference (t=3.16, P 0.05). The area under curve (AUC) value for miRNA-122 in the differentiation between CHB patients and control group was 0.92, and the AUC for predicting significant fibrosis and cirrhosis were 0.78 and 0.81, respectively. \\n \\n \\nConclusion \\nSerum miRNA-122 is closely related to the replication of HBV, liver damage and liver fibrosis stage. It may play a suppressive role on the HBV replication and the development of liver fibrosis. \\n \\n \\nKey words: \\nLiver cirrhosis; Hepatitis B virus; microRNA-122\",\"PeriodicalId\":10127,\"journal\":{\"name\":\"中华传染病杂志\",\"volume\":\"36 1\",\"pages\":\"533-536\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-09-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中华传染病杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1000-6680.2018.09.004\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华传染病杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1000-6680.2018.09.004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

目的评价慢性乙型肝炎(CHB)不同阶段肝纤维化患者血清miRNA -122的表达水平，并探讨其与临床参数的相关性。方法138例慢性乙型肝炎患者和30例健康对照。实时聚合酶链反应测定血清中miRNA-122的相对表达量。测定血清ALT、AST、γ-谷氨酰基转移酶(γ-GT)、碱性磷酸酶(ALP)、总胆红素(TBil)、白蛋白、凝血酶原时间(PT)、HBV DNA水平，并分析其与血清miRNA-122的相关性。对miRNA-122进行受试者工作特征(ROC)曲线分析，比较健康对照组和CHB纤维化患者。组间比较采用非参数t检验。结果慢性乙型肝炎患者与健康对照组血清miRNA-122相对表达量分别为4.41±1.32、1.47±0.58，差异有统计学意义(t=3.16, P < 0.05)。miRNA-122在CHB患者与对照组鉴别中的曲线下面积(AUC)值为0.92，预测显著纤维化和肝硬化的AUC值分别为0.78和0.81。结论血清miRNA-122与HBV复制、肝损伤及肝纤维化分期密切相关。它可能对HBV的复制和肝纤维化的发生有抑制作用。关键词:肝硬化;乙型肝炎病毒;微rna - 122

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Expression and clinical significance of serum microRNA-122 in liver fibrosis of patients with chronic hepatitis B

Objective To evaluate the expression of serum microRNA (miRNA)-122 in patients with chronic hepatitis B (CHB) with different stages of liver fibrosis, and to investigate its relevance with the clinical parameters. Methods Totally 138 CHB patients and 30 healthy controls were enrolled. Real-time polymerase chain reaction was used to measure the relative expression of miRNA-122 in serum. Serum levels of ALT, AST, γ-glutamyl-transferase (γ-GT), alkaline phosphatase (ALP), total bilirubin (TBil), albumin, prothrombin time (PT) and HBV DNA were measured, and their correlations with serum miRNA-122 were analyzed. Receiver operating characteristic (ROC)curev analysis was performed for miRNA-122 to compare healthy controls and CHB patients with fibrosis. Non-parametric t-test was used for comparison between groups. Results The relative expressions of serum miRNA-122 in patients with CHB and healthy controls were 4.41±1.32 and 1.47±0.58, respectively, with significantly statistical difference (t=3.16, P 0.05). The area under curve (AUC) value for miRNA-122 in the differentiation between CHB patients and control group was 0.92, and the AUC for predicting significant fibrosis and cirrhosis were 0.78 and 0.81, respectively. Conclusion Serum miRNA-122 is closely related to the replication of HBV, liver damage and liver fibrosis stage. It may play a suppressive role on the HBV replication and the development of liver fibrosis. Key words: Liver cirrhosis; Hepatitis B virus; microRNA-122

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

中华传染病杂志

自引率

0.00%

发文量

5280

期刊介绍： The Chinese Journal of Infectious Diseases was founded in February 1983. It is an academic journal on infectious diseases supervised by the China Association for Science and Technology, sponsored by the Chinese Medical Association, and hosted by the Shanghai Medical Association. The journal targets infectious disease physicians as its main readers, taking into account physicians of other interdisciplinary disciplines, and timely reports on leading scientific research results and clinical diagnosis and treatment experience in the field of infectious diseases, as well as basic theoretical research that has a guiding role in the clinical practice of infectious diseases and is closely integrated with the actual clinical practice of infectious diseases. Columns include reviews (including editor-in-chief reviews), expert lectures, consensus and guidelines (including interpretations), monographs, short monographs, academic debates, epidemic news, international dynamics, case reports, reviews, lectures, meeting minutes, etc.